BlackRock
BBOT

BlackRock’s BridgeBio Oncology BBOT Stock Holding History

BlackRock’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.4M Buy
2,154,040
+65,743
+3% +$549K ﹤0.01% 3396
2026
Q1 		$18.7M Buy
2,088,297
+3,460
+0.2% +$37.1K ﹤0.01% 3127
2025
Q4 		$26.1M Buy
2,084,837
+36,285
+2% +$440K ﹤0.01% 2940
2025
Q3 		$23.7M Buy
2,048,552
+549,687
+37% +$5.73M ﹤0.01% 2988
2025
Q2 		$15.9M Hold
1,498,865
– – ﹤0.01% 3158
2025
Q1 		$16.9M Hold
1,498,865
– – ﹤0.01% 3041
2024
Q4 		$15.7M Sell
1,498,865
-1,135
-0.1% -$11.9K ﹤0.01% 3190
2024
Q3 		$15.7M Hold
1,500,000
– – ﹤0.01% 3181
2024
Q2 		$15.3M Hold
1,500,000
– – ﹤0.01% 3141
2024
Q1 		$15.6M Buy
+1,500,000
New +$15.5M ﹤0.01% 3131

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock's BBOT Position: Q2 2026 in Review

BlackRock increased its BridgeBio Oncology (BBOT) stake by 3.1% in Q2 2026, buying an estimated $549K and bringing the position to 2,154,040 shares worth $16.4M. The position accounts for ﹤0.01% of the portfolio, ranked #3396.

BlackRock first reported a position in BBOT in Q1 2024 and has held it in 10 quarters since. The position peaked at $26.1M in Q4 2025. 57 funds tracked by Wall St. Rank hold BBOT as of Q2 2026.

  • BlackRock held 2,154,040 shares of BridgeBio Oncology worth $16.4M as of Q2 2026.
  • BlackRock bought 65,743 BridgeBio Oncology shares in Q2 2026, an estimated $549K.
  • BridgeBio Oncology made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #3396 holding.
  • BlackRock first reported a position in BridgeBio Oncology in Q1 2024 and has held it in 10 quarters since.
  • BlackRock's BridgeBio Oncology position peaked at $26.1M in Q4 2025.
  • 57 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.